Coronary microvascular disease (CMVD) is an underdiagnosed but significant contributor to the burden of ischemic heart disease, characterized by angina and myocardial infarction. The development of risk prediction models such as polygenic risk scores (PRS) for CMVD has been limited by a lack of large-scale genome-wide association studies (GWAS). However, there is significant overlap between CMVD and enrollment criteria for coronary artery disease (CAD) GWAS. In this study, we developed CMVD PRS models by selecting variants identified in a CMVD GWAS and applying weights from an external CAD GWAS, using CMVD-associated loci as proxies for the genetic risk. We integrated plasma proteomics, clinical measures from perfusion PET imaging, and PRS to evaluate their contributions to CMVD risk prediction in comprehensive machine and deep learning models. We then developed a novel unsupervised endotyping framework for CMVD from perfusion PET-derived myocardial blood flow data, revealing distinct patient subgroups beyond traditional case-control definitions. This imaging-based stratification substantially improved classification performance alongside plasma proteomics and PRS, achieving AUROCs between 0.65 and 0.73 per class, significantly outperforming binary classifiers and existing clinical models, highlighting the potential of this stratification approach to enable more precise and personalized diagnosis by capturing the underlying heterogeneity of CMVD. This work represents the first application of imaging-based endotyping and the integration of genetic and proteomic data for CMVD risk prediction, establishing a framework for multimodal modeling in complex diseases.

PURPOSEThe VISION study1 found that Lutetium-177 (177Lu)-PSMA-617 ("Lu-177") improved overall survival in metastatic castrate resistant prostate cancer (mCRPC). We assessed whether artificial intelligence enhanced PSMA imaging in mCRPC patients starting Lu-177 could identify those with better treatment outcomes. PATIENTS AND METHODSWe conducted a single site, tertiary center, retrospective cohort study in 51 consecutive mCRPC patients treated 2022-2024 with Lu-177. These patients had received most standard treatments, with disease progression. Planned treatment was Lu-177 every 6 weeks while continuing androgen deprivation therapy. Before starting treatment, PSMA images were analyzed for SUVmax and quantified tumor volume using artificial intelligence software (aPROMISE, Exinni Inc.). RESULTSFifty-one mCRPC patients were treated with Lu-177; 33 (65%) received 4 or more treatment cycles and these 33 had Kaplan-Meier median overall survival (OS) of 19.3 months and 23 (70%) surviving at 24 month data analysis. At first cycle Lu-177, these 33 had significantly more favorable levels of serum albumin, alkaline phosphatase, calcium, glucose, prostate specific antigen (PSA), ECOG performance status, and F18 PSMA imaging SUV-maximum values - reflecting PSMA "target expression". In a "protocol-eligibility" analysis, 30 of the 51 patients (59%) were considered "protocol-eligible" and 21 (41%) "protocol-ineligible" based on initial clinical parameters, as defined in Methods. "Protocol-eligible" patients had OS of 14.6 mo and 63% survival at 24 months. AI-enhanced F18 PSMA quantified imaging found "protocol-eligible" tumor volume in mL to be only 39% of the volume in "ineligible" patients. CONCLUSIONIn this cohort of mCRPC patients receiving Lu-177, pre-treatment AI-assisted F18 PSMA imaging finding higher PSMA SUV / lower tumor volume associated with the patients ability to have four or more treatment cycles, protocol eligibility, and better overall survival. KEY POINTSO_ST_ABSQuestionC_ST_ABSIn mCRPC patients initiating Lu-177 therapy, can AI-assisted F18 PSMA imaging identify patients who have better treatment outomes? Findings33 (65%) of a 51 consecutive patient mCRPC cohort were able to receive 4 or more cycles Lu-177. These patients had significantly more favorable serum albumin, alkaline phosphatase, calcium, glucose, PSA, performance status, and higher AI-PSMA scan SUV-maximum values, with a trend toward lower PSMA tumor volumes in mL. They had Kaplan-Meier median OS of 19.3 months and 70% survived at 24 months. AI-enhanced PSMA tumor volumes (mL) in "protocol eligible" patients were significantly lower - only 40% - than tumor volumes of "protocol ineligible" patients. MeaningIn this cohort of mCRPC patients receiving Lu-177, pre-treatment AI-assisted F18 PSMA imaging finding higher PSMA SUV / lower tumor volume associated with the patients ability to have four or more treatment cycles, protocol eligibility, and better overall survival.

Dynamic Positron Emission Tomography (PET) scans offer rich spatiotemporal data for detecting malignancies, but their high-dimensionality and noise pose significant challenges. We introduce a novel framework, the Equivariant Spatiotemporal Transformer with MDL-Guided Feature Selection (EST-MDL), which integrates group-theoretic symmetries, Kolmogorov complexity, and Minimum Description Length (MDL) principles. By enforcing spatial and temporal symmetries (e.g., translations and rotations) and leveraging MDL for robust feature selection, our model achieves improved generalization and interpretability. Evaluated on three realworld PET datasets--LUNG-PET, BRAIN-PET, and BREAST-PET--our approach achieves AUCs of 0.94, 0.92, and 0.95, respectively, outperforming CNNs, Vision Transformers (ViTs), and Graph Neural Networks (GNNs) in AUC, sensitivity, specificity, and computational efficiency. This framework offers a robust, interpretable solution for malignancy detection in clinical settings.

PSMA PET/CT imaging has been increasingly utilized in the management of patients with metastatic prostate cancer (mPCa). Imaging biomarkers derived from PSMA PET may provide improved prognostication and prediction of treatment response for mPCa patients. This study investigates a novel deep learning-derived imaging biomarker framework for outcome prediction using multi-modal PSMA PET/CT and clinical features. A single institution cohort of 99 mPCa patients with 396 lesions was evaluated. Imaging features were extracted from cropped lesion areas and combined with clinical variables including body mass index, ECOG performance status, prostate specific antigen (PSA) level, Gleason score, and treatments received. The PSA progression-free survival (PFS) model was trained using a ResNet architecture with a Cox proportional hazards loss function using five-fold cross-validation. Performance was assessed using concordance index (C-index) and Kaplan-Meier survival analysis. Among evaluated model architectures, the ResNet-18 backbone offered the best performance. The multi-modal deep learning framework achieved a 5-fold cross-validation C-index ranging from 0.75 to 0.94, outperforming models incorporating imaging only (0.70-0.89) and clinical features only (0.53-0.65). Kaplan-Meir survival analysis performed on the deep learning-derived predictions demonstrated clear risk stratification, with a median PSA progression free survival (PFS) of 19.7 months in the high-risk group and 26 months in the low-risk group (P < 0.001). Deep learning-derived imaging biomarker based on PSMA PET/CT can effectively predict PSA PFS for mPCa patients. Further clinical validation in prospective cohorts is warranted.

PurposePrecise quantification of myocardial blood flow (MBF) and flow reserve (MFR) in 18F-flurpiridaz PET significantly relies on motion correction (MC). However, the manual frame-by-frame correction leads to significant inter-observer variability, time-consuming, and requires significant experience. We propose a deep learning (DL) framework for automatic MC of 18F-flurpiridaz PET. MethodsThe method employs a 3D ResNet based architecture that takes 3D PET volumes and outputs motion vectors. It was validated using 5-fold cross-validation on data from 32 sites of a Phase III clinical trial (NCT01347710). Manual corrections from two experienced operators served as ground truth, and data augmentation using simulated vectors enhanced training robustness. The study compared the DL approach to both manual and standard non-AI automatic MC methods, assessing agreement and diagnostic accuracy using minimal segmental MBF and MFR. ResultsThe area under the receiver operating characteristic curves (AUC) for significant CAD were comparable between DL-MC MBF, manual-MC MBF from Operators (AUC=0.897,0.892 and 0.889, respectively; p>0.05), standard non-AI automatic MC (AUC=0.877; p>0.05) and significantly higher than No-MC (AUC=0.835; p<0.05). Similar findings were observed with MFR. The 95% confidence limits for agreement with the operator were {+/-}0.49ml/g/min (mean difference = 0.00) for MFR and {+/-}0.24ml/g/min (mean difference = 0.00) for MBF. ConclusionDL-MC is significantly faster but diagnostically comparable to manual-MC. The quantitative results obtained with DL-MC for MBF and MFR are in excellent agreement with those manually corrected by experienced operators compared to standard non-AI automatic MC in patients undergoing 18F-flurpiridaz PET-MPI.

BackgroundPositron emission tomography (PET)/CT for myocardial perfusion imaging (MPI) provides multiple imaging biomarkers, often evaluated separately. We developed an artificial intelligence (AI) model integrating key clinical PET MPI parameters to improve the diagnosis of obstructive coronary artery disease (CAD). MethodsFrom 17,348 patients undergoing cardiac PET/CT across four sites, we retrospectively enrolled 1,664 subjects who had invasive coronary angiography within 180 days and no prior CAD. Deep learning was used to derive coronary artery calcium score (CAC) from CT attenuation correction maps. XGBoost machine learning model was developed using data from one site to detect CAD, defined as left main stenosis [&ge;]50% or [&ge;]70% in other arteries. The model utilized 10 image-derived parameters from clinical practice: CAC, stress/rest left ventricle ejection fraction, stress myocardial blood flow (MBF), myocardial flow reserve (MFR), ischemic and stress total perfusion deficit (TPD), transient ischemic dilation ratio, rate pressure product, and sex. Generalizability was evaluated in the remaining three sites--chosen to maximize testing power and capture inter-site variability--and model performance was compared with quantitative analyses using the area under the receiver operating characteristic curve (AUC). Patient-specific predictions were explained using shapley additive explanations. ResultsThere was a 61% and 53% CAD prevalence in the training (n=386) and external testing (n=1,278) set, respectively. In the external evaluation, the AI model achieved a higher AUC (0.83 [95% confidence interval (CI): 0.81-0.85]) compared to clinical score by experienced physicians (0.80 [0.77-0.82], p=0.02), ischemic TPD (0.79 [0.77-0.82], p<0.001), MFR (0.75 [0.72-0.78], p<0.001), and CAC (0.69 [0.66-0.72], p<0.001). The models performances were consistent in sex, body mass index, and age groups. The top features driving the prediction were stress/ischemic TPD, CAC, and MFR. ConclusionAI integrating perfusion, flow, and CAC scoring improves PET MPI diagnostic accuracy, offering automated and interpretable predictions for CAD diagnosis.

BackgroundInadequate pharmacologic stress may limit the diagnostic and prognostic accuracy of myocardial perfusion imaging (MPI). The splenic ratio (SR), a measure of stress adequacy, has emerged as a potential imaging biomarker. ObjectivesTo evaluate the prognostic value of artificial intelligence (AI)-derived SR in a large multicenter 82Rb-PET cohort undergoing regadenoson stress testing. MethodsWe retrospectively analyzed 10,913 patients from three sites in the REFINE PET registry with clinically indicated MPI and linked clinical outcomes. SR was calculated using fully automated algorithms as the ratio of splenic uptake at stress versus rest. Patients were stratified by SR into high ([&ge;]90th percentile) and low (<90th percentile) groups. The primary outcome was major adverse cardiovascular events (MACE). Survival analysis was conducted using Kaplan-Meier and Cox proportional hazards models adjusted for clinical and imaging covariates, including myocardial flow reserve (MFR [&ge;]2 vs. <2). ResultsThe cohort had a median age of 68 years, with 57% male patients. Common risk factors included hypertension (84%), dyslipidemia (76%), diabetes (33%), and prior coronary artery disease (31%). Median follow-up was 4.6 years. Patients with high SR (n=1,091) had an increased risk of MACE (HR 1.18, 95% CI 1.06-1.31, p=0.002). Among patients with preserved MFR ([&ge;]2; n=7,310), high SR remained independently associated with MACE (HR 1.44, 95% CI 1.24-1.67, p<0.0001). ConclusionsElevated AI-derived SR was independently associated with adverse cardiovascular outcomes, including among patients with preserved MFR. These findings support SR as a novel, automated imaging biomarker for risk stratification in 82Rb PET MPI. Condensed AbstractAI-derived splenic ratio (SR), a marker of pharmacologic stress adequacy, was independently associated with increased cardiovascular risk in a large 82Rb PET cohort, even among patients with preserved myocardial flow reserve (MFR). High SR identified individuals with elevated MACE risk despite normal perfusion and flow findings, suggesting unrecognized physiologic vulnerability. Incorporating automated SR into PET MPI interpretation may enhance risk stratification and identify patients who could benefit from intensified preventive care, particularly when traditional imaging markers appear reassuring. These findings support SR as a clinically meaningful, easily integrated biomarker in stress PET imaging.